MedTrace Logo

Effect of GnRH Agonist in FET

NCT07653282 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 122

Last updated 2026-06-17

No results posted yet for this study

Summary

To evaluate the impact of single dose GnRH agonist administration as luteal phase support on pregnancy outcomes in frozen ICSI cycle

Conditions

  • GnRH Agonist

Interventions

DRUG

GnRH agonist

women undergoing frozen ICSI cycles receiving progesterone + GnRH agonist for luteal phase support.

Sponsors & Collaborators

  • Woman's Health University Hospital, Egypt

    collaborator OTHER

  • Assiut University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
39 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-08-01
Primary Completion
2027-08-01
Completion
2028-08-01
FDA Drug
Yes

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07653282 on ClinicalTrials.gov